Yuka Sugimoto

2.5k total citations
79 papers, 1.5k citations indexed

About

Yuka Sugimoto is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Yuka Sugimoto has authored 79 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 24 papers in Genetics and 17 papers in Molecular Biology. Recurrent topics in Yuka Sugimoto's work include Acute Myeloid Leukemia Research (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Yuka Sugimoto is often cited by papers focused on Acute Myeloid Leukemia Research (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Yuka Sugimoto collaborates with scholars based in Japan, United States and Brazil. Yuka Sugimoto's co-authors include Mikkael A. Sekeres, Hideki Makishima, Ramón V. Tiu, Jaroslaw P. Maciejewski, Fabı́ola Traina, Hadrian Szpurka, Valeria Visconte, Alan F. List, Kohshi Ohishi and C. O'Keefe and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Yuka Sugimoto

70 papers receiving 1.5k citations

Peers

Countries citing papers authored by Yuka Sugimoto

Since Specialization

Citations

This map shows the geographic impact of Yuka Sugimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuka Sugimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuka Sugimoto more than expected).

Fields of papers citing papers by Yuka Sugimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuka Sugimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuka Sugimoto. The network helps show where Yuka Sugimoto may publish in the future.

Co-authorship network of co-authors of Yuka Sugimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Yuka Sugimoto. A scholar is included among the top collaborators of Yuka Sugimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuka Sugimoto. Yuka Sugimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation 2024 ·Hematology ·(unknown), Yuka Sugimoto, (unknown), (unknown), Makoto Ikejiri, Yasuyuki Watanabe, (unknown), Koji Oka, Isao Tawara	0
2	Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera 2024 ·International Journal of Hematology ·Keita Kirito, Yuka Sugimoto, Akihiko Gotoh, Katsuto Takenaka, (unknown), (unknown), Shuichi Shirane, Masafumi Ito, Oleh Zagrijtschuk, Albert Qin, (unknown), Toshiaki Sato, Norio Komatsu, Kazuya Shimoda	4
3	A Simple Diagnostic Algorithm for the Prediction of JAK2 Mutation Status in Erythrocytosis Based on Complete Blood Count Data: A Multi-Center Retrospective Analysis 2024 ·Blood ·(unknown), Yuka Sugimoto, (unknown), (unknown), Eri Miyata, Atsushi Fujieda, Hiroyuki Miyashita, (unknown), Shigehisa Tamaki, Kohshi Ohishi, Isao Tawara	0
4	A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy 2024 ·Blood ·Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, (unknown), Jean‐Jacques Kiladjian, (unknown), Harinder Gill, Kristen Pettit, David M. Ross, (unknown), (unknown), Ahmet Muzaffer Demir, (unknown), (unknown), (unknown), (unknown), (unknown), Uzor C. Ogbu, Keita Kirito	0
5	Discordance of light chain isotypes between serum and glomerular deposits in proliferative glomerulonephritis with monoclonal IgG deposits: a case report and review of the literature 2023 ·BMC Nephrology ·Shoko Miura, Kan Katayama, Yuka Sugimoto, (unknown), (unknown), (unknown), (unknown), (unknown), Tomohiro Murata, Isao Tawara, Kaoru Dohi	2
6	Clinical Utility of Flow Cytometry for Detection of Anti-Jk<sup>b</sup> IgM in Acute Haemolytic Transfusion Reaction 2023 ·Internal Medicine ·(unknown), (unknown), (unknown), Yuka Sugimoto, Kohshi Ohishi, Isao Tawara, Eiji Usui, Shigehisa Tamaki	1
7	MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia 2021 ·International Journal of Hematology ·Yuka Sugimoto, (unknown), Kohshi Ohishi, Maki Nakamura, Makoto Ikejiri, Kaname Nakatani, Minoru Mizutani, Shigehisa Tamaki, (unknown), Isao Tawara, Naoyuki Katayama	2
8	Light chain proximal tubulopathy diagnosed solely by electron microscopy of a renal biopsy specimen in a patient with monoclonal gammopathy of undetermined significance 2021 ·International Journal of Hematology ·Yuka Sugimoto, Mika Fujimoto, (unknown), (unknown), Tomohiro Murata, T Tsukada	3
9	Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia 2020 ·Journal of Clinical and Experimental Hematopathology ·Noriaki Kawano, Tetsuo Maeda, Sayaka Kawano, (unknown), Akiyoshi Takami, (unknown), (unknown), Kiyoshi Yamashita, Takao Kodama, (unknown), Yuka Sugimoto, Toshihiko Imamura, Yasuo Mori, Hidenobu Ochiai, Tomonori Hidaka, Kazuya Shimoda, (unknown), Ikuo Kikuchi	1
10	O-33 The Associations of Oral Health-related Quality of Life with Stress in Japanese Men and Women 2013 ·Mariko Naito, Yuka Sugimoto, Nana Fukuda, Shino Suma, Kenji Wakai	1
11	Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide 2012 ·Journal of Hematology & Oncology ·Yuka Sugimoto, Mikkael A. Sekeres, Hideki Makishima, Fabı́ola Traina, Valeria Visconte, Anna Jankowska, Andrés Jerez, Hadrian Szpurka, Christine L. O’Keefe, Kathryn M Guinta, Manuel Afable, Ramón V. Tiu, Kathy L. McGraw, Alan F. List, Jaroslaw P. Maciejewski	18
12	Efficacy of Rabbit Anti-Thymocyte Globulin (ATG) Compared to Horse ATG In Severe Aplastic Anemia 2010 ·Blood ·(unknown), Mohammed Shaik, Yuka Sugimoto, Michael J. Clemente, Ramón V. Tiu, Sanjay Mohan, Nelli Bejanyan, Paul Elson, Matt Kalaycio, Anjali S. Advani, Ronald Sobecks, Alan Lichtin, Mikkael A. Sekeres, Jaroslaw P. Maciejewski	2
13	Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations 2010 ·British Journal of Haematology ·Yuka Sugimoto, Hideki Muramatsu, Hideki Makishima, Courtney Prince, Anna Jankowska, Nao Yoshida, Yinyan Xu, Nobuhiro Nishio, Asahito Hama, Hiroshi Yagasaki, Yoshiyuki Takahashi, Koji Kato, Atsushi Manabe, Seiji Kojima, Jaroslaw P. Maciejewski	53
14	Notch ligand Delta‐1 differentially modulates the effects of gp130 activation on interleukin‐6 receptor α‐positive and ‐negative human hematopoietic progenitors 2007 ·Cancer Science ·(unknown), Kohshi Ohishi, Naoyuki Katayama, Keizo Kato, (unknown), Yuka Sugimoto, Eri Miyata, Hiroshi Shiku, Masahiro Masuya, Junji Nishioka, Tsutomu Nobori, Mitsuo Nishikawa, Yoshimasa Inagaki, Hidefumi Hiramatsu, Tatsutoshi Nakahata	12
15	Development of Mixed-Type Autoimmune Hemolytic Anemia and Evans' Syndrome following Chicken Pox Infection in a Case of Low-Titer Cold Agglutinin Disease 2006 ·International Journal of Hematology ·(unknown), Masahiro Masuya, Naoyuki Katayama, Eri Miyata, Yuka Sugimoto, (unknown), (unknown), Kohshi Ohishi, Nobuyuki Minami, Hiroshi Shiku, Tsutomu Nobori	8
16	Molecular and phenotypic analysis of Philadelphia chromosome-positive bilineage leukemia: possibility of a lineage switch from T-lymphoid leukemic progenitor to myeloid cells 2006 ·Cancer Genetics and Cytogenetics ·Fumihiko Monma, Kazuhiro Nishii, (unknown), (unknown), Shunji Yamamori, Eiji Usui, Yuka Sugimoto, Felipe Lorenzo, Naoyuki Katayama, Hiroshi Shiku	19
17	Differential cell division history between neutrophils and macrophages in their development from granulocyte–macrophage progenitors 2006 ·British Journal of Haematology ·Yuka Sugimoto, Naoyuki Katayama, Masahiro Masuya, Eri Miyata, Masaya Ueno, Kohshi Ohishi, Kazuhiro Nishii, Nobuyuki Takakura, Hiroshi Shiku	10
18	Acute myeloid leukemia with t(8;21)(q22;q22) manifesting as granulocytic sarcomas in the rhinopharynx and external acoustic meatus at relapse after high-dose cytarabine: case report and review of the literature 2004 ·The Hematology Journal ·Yuka Sugimoto, Kazuhiro Nishii, Miho Sakakura, (unknown), Eiji Usui, (unknown), (unknown), Hiroyuki Miyashita, (unknown), Naoyuki Katayama, Hiroshi Shiku	22
19	Hormonal control of ornithine decarboxylase and spermidine/spermine N1-acetyltransferase activities by sex steroid hormones in the uterus of ovariectomized rats 1999 ·Hiroshige Hibasami, (unknown), Takashi Sugiyama, (unknown), Kozo Nakanishi, Yasutomo Ishii, Yuka Sugimoto, Kazuhisa Nakashima	1
20	Carbohydrate malabsorption following acarbose administration 1998 ·Diabetic Medicine ·Hiroshi Sobajima, Mika Mori, T. Niwa, (unknown), Yuka Sugimoto, (unknown), Satoru Naruse, Takaharu Kondo, T Hayakawa	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact